Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens-Reference-Cited by-同舟云学术

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Published:2017-12 Issue:1 Volume:17 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Seymour John F.^ORCID,Döhner Hartmut,Butrym Aleksandra,Wierzbowska Agnieszka,Selleslag Dominik,Jang Jun Ho,Kumar Rajat,Cavenagh James,Schuh Andre C.,Candoni Anna,Récher Christian,Sandhu Irwindeep,del Castillo Teresa Bernal,Al-Ali Haifa Kathrin,Falantes Jose,Stone Richard M.,Minden Mark D.,Weaver Jerry,Songer Steve,Beach C. L.,Dombret Hervé

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-017-3803-6.pdf

Reference21 articles.

1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–52. doi: 10.1056/NEJMra1406184 .

2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544 .

3. Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood. 2010;116(15):2742–51. doi:blood-2010-04-279794 [pii]; 10.1182/blood-2010-04-279794 [doi].

4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. doi:blood-2009-03-209262 [pii]; 10.1182/blood-2009-03-209262 [doi].

5. Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113(9):1906–8. doi: 10.1182/blood-2008-10-182782 .

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia;Leukemia Research;2024-09

2. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study;European Journal of Cancer;2024-05

3. Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy;Cancer Medicine;2024-02

4. Assessment of 2022 European LeukemiaNet risk classification system in real‐world cohort from China;Cancer Medicine;2023-12

5. Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia;Leukemia & Lymphoma;2023-09-21